XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S., it is estimated there are more than 40,000 cases of Acinetobacter each year and approximately 40...

Related Keywords

United States ,Pavel Raifeld ,Margaret Koziel ,Tragiannidisa Acinetobacter ,Yuk National Prevalence ,Innoviva Specialty Therapeutics Inc ,Jolla Pharmaceutical Company ,Entasis Therapeutics Inc ,Innoviva Inc ,Exchange Commission ,National Review Drug Discovery ,Glaxo Group Limited ,Centers For Disease ,Urgent Public Health Threat In United States ,World Health Organization ,Drug Administration ,Securities Exchange ,Nasdaq ,International Journal Of Infectious Disease ,Innoviva Specialty Therapeutics ,Chief Executive Officer ,Infectious Disease ,Chief Medical Officer ,Disease Control ,Full Prescribing Information ,Specialty Therapeutics ,Specialty Therapeutic ,Long Acting Beta ,Collaboration Agreement ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Single Pathogen Antibacterial ,National Review Drug ,International Journal ,Safety Of Sulbactam ,Durlobactam Versus Colistin ,Non Inferiority Clinical Trial ,Published May ,Loading Dose Colistin ,Carbapenem Resistant Acinetobacter ,Critically Ill ,Risk Factors ,Clinical Presentation ,Antibiotic Resistance ,Resistant Acinetobacter ,Health Organization ,